CSL Ltd./ AU000000CSL8 /
2024-06-06 3:48:13 PM | Chg. +7.5000 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
192.0000USD | +4.07% | 100 Turnover: 19,200 |
-Bid Size: - | -Ask Size: - | 92.48 bill.USD | 1.23% | 42.14 |
GlobeNewswire
05-22
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-...
GlobeNewswire
05-09
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Re...
GlobeNewswire
05-08
Carlyle Secured Lending, Inc. Announces Financial Results For First Quarter Ended 2024, Declares Sec...
GlobeNewswire
05-07
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
GlobeNewswire
04-30
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Tr...
GlobeNewswire
04-30
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Ap...
GlobeNewswire
04-24
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for ...
GlobeNewswire
04-16
Eureka Shipping Announces Construction of New Cutting-Edge Cement Carrier for Great Lakes Trade
GlobeNewswire
03-11
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administrat...
GlobeNewswire
03-04
Carlyle Secured Lending, Inc. Names Justin Plouffe CEO and Member of the Board of Directors
GlobeNewswire
02-26
Carlyle Secured Lending, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results, Increas...
GlobeNewswire
02-23
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
02-15
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results